Summary & Overview
HCPCS Level II J9160: Injection, Denileukin Diftitox, 300 Micrograms
HCPCS Level II code J9160 denotes the injection of denileukin diftitox, 300 micrograms, an injectable biologic therapy used in specific oncologic or hematologic indications. Nationally, identification and correct use of this HCPCS Level II code matter for accurate drug billing, inventory tracking, and payer reimbursement alignment for outpatient and clinic-administered biologic therapies.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what the code represents, the typical sites of service where this treatment is administered, and an overview of documentation and billing contexts relevant to injectable biologics. The publication outlines expected claims line elements, common modifier usage patterns (listed separately), and the clinical setting in which J9160 is most often billed.
This summary equips clinicians, billing professionals, and policy analysts with practical context for billing and coding workflows, payer interactions, and administrative considerations related to denileukin diftitox administration. Data not available in the input is noted where applicable, and the content focuses on national-level applicability rather than state-specific rules.
Billing Code Overview
HCPCS Level II code J9160 describes an injection of denileukin diftitox, 300 micrograms. This entry represents a single-dose injectable biological therapy, typically administered to treat certain hematologic or oncologic conditions where denileukin diftitox is indicated.
Service Type: Injectable biologic therapy
Typical Site of Service: Outpatient infusion clinic or hospital outpatient department; may also be administered in physician office settings equipped for parenteral biologic therapy
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with relapsed cutaneous T-cell lymphoma presents for outpatient infusion of denileukin diftitox. The infusion is ordered by the oncology team after prior systemic therapies produced inadequate response. Pre-infusion evaluation includes vital signs, review of prior infusion reactions, baseline laboratory studies (CBC, CMP), and confirmation of allergy history. The medication, billed as J9160 for a 300 microgram vial, is prepared by pharmacy under aseptic technique and delivered to the infusion suite. An oncology nurse verifies patient identity, consent, and premedication orders (antihistamine, corticosteroid) to reduce risk of hypersensitivity. The drug is administered intravenously per the product-specific protocol with continuous monitoring for infusion-related reactions; vital signs are documented at baseline and at regular intervals. If a moderate or severe reaction occurs, the infusion is slowed or stopped and emergency protocols are enacted. Post-infusion observation is conducted for the recommended interval, adverse events are documented, and instructions for delayed reactions are provided. Billing uses J9160 with applicable modifier(s) reflecting circumstances of the service and the claim is submitted to the patient’s commercial or government payor for outpatient drug administration.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 |